Impax to co-promote Wyeth's Pristiq

29 March 2009

Impax Laboratories says that, beginning July 1, the firm's specialty brand products division will co-promote Wyeth's Pristiq  (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor as a  treatment for adult patients with major depressive disorder. Impax  Pharmaceuticals will utilize its 66 neurology-focused sales force to  promote he product.

Impax Labs entered into a three-year co-promotion agreement with Wyeth  in July 2008 to detail a product then to-be named by the drug major for  neurologists. Impax will receive a fee for each detail delivered. Other  terms of this agreement are confidential and were not disclosed.

Wyeth is in the process of being acquired by US pharmaceutical leviathan  Pfizer for $68.0 billion (Marketletter February 2).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight